Repligen Corporation Announces Closing of Public Offering of $312.2 Million, Including Full Exercise of Underwriters’ Optio...
December 10 2020 - 4:17PM
Repligen Corporation (NASDAQ: RGEN) today announced the closing of
its previously announced underwritten public offering of an
aggregate of 1.725 million shares of its common stock at a public
offering price of $181 per share for gross proceeds, before
deducting underwriting discounts and commissions and estimated
offering expenses, of approximately $312.2 million, which includes
the exercise in full of the underwriters’ option to purchase
225,000 additional shares. The offering of the shares is expected
to result in approximately $298 million in net proceeds to Repligen
after deducting underwriting discounts and commissions and other
estimated offering expenses payable by Repligen.
Repligen Corporation intends to use the net proceeds from this
offering for working capital and other general corporate purposes.
Net proceeds from this offering may also be used to fund possible
acquisitions of, or investments in, complementary businesses,
products, services and technologies. Repligen has not entered into
any agreements or commitments with respect to any acquisitions or
investments at this time.
J.P. Morgan Securities LLC and Stifel, Nicolaus & Company,
Incorporated acted as joint book-running managers for the offering.
Craig-Hallum Capital Group, Stephens Inc., SVB Leerink LLC and
William Blair & Company, L.L.C. acted as co-managers for the
offering.
These securities were issued and sold pursuant to an
automatically effective shelf registration statement (including a
base prospectus) that was previously filed with the Securities and
Exchange Commission (“SEC”). A final prospectus supplement relating
to this offering has been filed with the SEC. Copies of the final
prospectus supplement and the accompanying prospectus relating to
this offering may be obtained from J.P. Morgan Securities LLC,
Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email
at prospectus-eq_fi@jpmchase.com and from Stifel, Nicolaus &
Company, Incorporated, Attention: Syndicate, One Montgomery Street,
Suite 3700, San Francisco, California 94104, by telephone at (415)
364-2720, or by email at syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Repligen Corporation Repligen Corporation
is a global life sciences company that develops and commercializes
highly innovative bioprocessing technologies and systems that
increase efficiencies in the process of manufacturing biological
drugs. Our primary customers are biopharmaceutical drug developers
and contract development and manufacturing organizations (CDMOs)
worldwide. Our corporate headquarters are located in Waltham,
Massachusetts, with additional administrative and manufacturing
operations worldwide. The majority of our manufacturing sites are
located in the U.S. (California, Massachusetts, New Jersey and New
York), and outside of the U.S. we have sites in Estonia, Germany,
Ireland, the Netherlands and Sweden.
Cautionary Language Concerning Forward-Looking
StatementsThis press release contains forward-looking
statements regarding our future business expectations, which are
subject to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Investors are cautioned that
statements in this press release which are not strictly historical
statements constitute forward-looking statements, including,
without limitation, statements regarding the anticipated use of
proceeds of the proposed offering, constitute forward-looking
statements identified by words like “believe,” “expect,” “may,”
“will,” “should,” “seek,” “anticipate,” or “could” and similar
expressions. Such forward-looking statements are subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those anticipated, including, without
limitation and uncertainties related to market conditions. These
and other risks and uncertainties are described in greater detail
in the section entitled “Risk Factors” in Repligen’s most recent
Annual Report on Form 10-K for the year ended December 31, 2019 and
in our Quarterly Report on Form 10-Q for the quarter ended March
31, 2020 on file with the Securities and Exchange Commission and
the other reports that Repligen periodically files with the
Securities and Exchange Commission. Actual results may differ
materially from those Repligen contemplated by these
forward-looking statements. These forward-looking statements
reflect management’s current views and Repligen does not undertake
to update any of these forward-looking statements to reflect a
change in its views or events or circumstances that occur after the
date hereof except as required by law.
Source:
Repligen Corporation Sondra Newman Global Head of Investor
Relationssnewman@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024